
Droice Labs develops AI middleware solutions, including Hawk and SuperLineage, that transform raw, complex real-world data (RWD) such as EHR, labs, and claims into high-quality, analysis-ready data for clinical trials. Their technology enables lossless data processing, traceability, and measurable data quality, addressing the challenges of using RWD in evidence generation for pharmaceutical and healthcare industries. Hawk processes diverse global data sources ethically and compliantly under HIPAA and GDPR, while SuperLineage provides element-level lineage for scalable validation of RWD, supporting regulatory submissions. The company targets pharma and healthcare enterprises, leveraging advanced machine learning, natural language processing, and data engineering to improve clinical trial efficiency and patient care personalization at scale.

Droice Labs develops AI middleware solutions, including Hawk and SuperLineage, that transform raw, complex real-world data (RWD) such as EHR, labs, and claims into high-quality, analysis-ready data for clinical trials. Their technology enables lossless data processing, traceability, and measurable data quality, addressing the challenges of using RWD in evidence generation for pharmaceutical and healthcare industries. Hawk processes diverse global data sources ethically and compliantly under HIPAA and GDPR, while SuperLineage provides element-level lineage for scalable validation of RWD, supporting regulatory submissions. The company targets pharma and healthcare enterprises, leveraging advanced machine learning, natural language processing, and data engineering to improve clinical trial efficiency and patient care personalization at scale.
What they do: AI middleware (Droice Hawk) that converts messy RWD (EHR, claims, labs, clinical text) into analysis-ready, traceable data for clinical trials and RWE
Key products: Droice Hawk, Flamingo (medical NLU), SuperLineage (element-level lineage)
Headquarters: New York, NY
Team size: ~19 employees
Funding signal: Multiple early rounds and non-equity assistance; known program investors include PharmStars and SAP.iO
Real-world data (RWD) preparation and validation for clinical trials, real-world evidence, and regulatory/reimbursement decision-making.
Healthtech / AI for healthcare
Dealroom lists an entry dated Apr 2016 (amount not disclosed)
Dealroom lists an entry dated Sep 2016 (amount not disclosed)
Dealroom lists an entry dated Apr 2017 (amount not disclosed)
Dealroom lists an entry dated Oct 2017 (amount not disclosed)
Dealroom lists an entry dated Sep 2019 (amount not disclosed)
Latest listed funding date per company snapshot (amount not disclosed)
“Program and strategic investors including PharmStars and SAP.iO; additional investors reported in databases include Almaworks and Dorm Room Fund”